messag updat novo buy dkk model ahead
earn februari continu see novo well-posit
deliv growth driven franchis includ uptak ozemp disciplin
cost-manag capit alloc unchang market environ
overal categori near-term maintain buy rate
increas pt dkk dkk result estim
chang modest fx tailwind
oral semaglutid detail data regulatori updat next major potenti catalyst
novo novo current plan file regulatori approv oral semaglutid
us eu novo nordisk activ discuss fda obtain
cardiovascular cv indic semaglutid differ formul base
pool cv data sustain ozemp pioneer oral semaglutid
date semaglutid demonstr clinic meaning benefit consist overal
class leader novo victoza lli buy trulic unclear
us whether fda support novo plan includ cv benefit clinic
data section drug without addit oral semaglutid studi remain posit
growth novo franchis inclus cv benefit label would
upsid expect
model updat novo estim sale ep dkk dkk
respect estim sale ep dkk dkk
respect repres cer sale growth oper growth
near top-end novo guidanc respect
modest consensu sale ep respect primarili
driven growth increment oper leverag driven growth
franchis saxenda xultophi off-set partial semaglutid pipelin activ nash
obes rais ozemp number lower victoza base us volum
balanc rais overal contribut two product mid-singl digit
base current currenc rate expect fx provid
modest tailwind sale
page analyst certif import disclosur
valuat risk
valu novo dkk dkk result estim chang modest
fx tailwind valuat base dcf analysi assum wacc
line larg cap pharma peer termin growth rate
downsid risk includ price pressur diabet persist overhang novo busi
clinic failur regulatori delay next-gen oral
page analyst certif import disclosur
dkk million except ep
sourc compani report guggenheim llc estim
page analyst certif import disclosur
dkk million except ep
sourc compani report guggenheim llc estim
page analyst certif import disclosur
